June 27, 2007 EUROPEAN JOURNAL OF MEDICAL RESEARCH 61 out HAART had pruritus (38%) and 18 dry skin (40,9%). IgE was elevated in 43 patients, 8 <strong>of</strong> those had a CD4 cell count
62 EUROPEAN JOURNAL OF MEDICAL RESEARCH June 27, 2007 to immune reconstitution frequently presenting with atypical clinical signs and symptoms. Results: A 62 year old HIV-infected patient reported development <strong>of</strong> a focal swelling <strong>of</strong> the dorsum <strong>of</strong> the left hand resembling lipomatosis 2 weeks after switching to an antiretroviral therapy regimen consisting <strong>of</strong> AZT, 3TC, and lopinavir. At that time CD4 cell count was 247/l and viral load below the limit <strong>of</strong> detection. Four months later therapy was changed to liponavir monotherapy because <strong>of</strong> toxicity (anemia) and further two months later the patient realised a similar swelling <strong>of</strong> the dorsum <strong>of</strong> his right hand with progress over two months. The tumor <strong>of</strong> the left hand was then diagnosed as tenosynovitis based on magnet resonance tomography (MRT) revealing a non-infiltrating fluidlike process with a size <strong>of</strong> 7x16x25 mm and peripheral vascularisation consistant with an inflammatory process. He complained about no pain or other signs and symptoms. He had been on different combination therapies including non-nucleoside and nucleoside analogue reverse transcriptase inhibitors for three years with good immunological response (CD4 cells 8/l, > 750.000 copies HIV-RNA copies/ml plasma before therapy). He had never had lipomas before in his live nor did any <strong>of</strong> his familiy members. After initiation <strong>of</strong> lopinavir therapy increase <strong>of</strong> C-reactive protein (CRP) to 46.9 mg/l was observed. Because <strong>of</strong> the close time relation <strong>of</strong> the hand swelling and start <strong>of</strong> lopinavir treatment, the therapy was switch to atazanavir 300mg QD, ritonavir 100mg BID, and saquinavir 500mg BID. This was followed by immediate and complete disappearance <strong>of</strong> the left and significant reduction <strong>of</strong> the right dorsal hand lipomas within a few weeks. Six weeks after the last therapy switch CRP had declined to 27.3 mg/l. Conclusion: Tenosynovitis associated with protease inhibitor therapy can be misdiagnosed as lipomatosis. Whether this patient suffered from either immune reconstitution syndrome or rather drug related toxicity remains unclear. Replacement <strong>of</strong> lopinavir led to complete clinical resolution and drop <strong>of</strong> inflammatory parameters. B.26 (Vortrag) Untreated HIV patients with undetectable virus – What happens to the CD4 cells? Eger J. 1 , Wolf E. 2 , Gölz J. 3 , Brust J. 4 , Ulmer A. 5 , Nzimegne-Gölz S. 3 , Mosthaf F. 6 , Vogel M. 7 , Rockstroh J. 7 , Leistner I. 8 , Mayr C. 8 , Carganico A. 9 , Mueller M. 5 , Jäger H. 1 , NoVi Study Group 1 HIV <strong>Research</strong> and Clinical Care Centre Munich, Munich, Germany, 2 MUC <strong>Research</strong>, Munich, Germany, 3 HIV Outpatient Practice Kaiserdamm, Berlin, Germany, 4 Private Practice for Internal Medicine, Hematology and Oncology, Mannheim, Germany, 5 HIV Outpatient Practice, Stuttgart, Germany, 6 Private Practice for Hematology, Oncology and Infectious Diseases, Karlsruhe, Germany, 7 University Hospital <strong>of</strong> Bonn, Bonn, Germany, 8 Ärzteforum Seestraße, Berlin, Germany, 9 HIV Outpatient Practice, Berlin, Germany Background: To evaluate whether low level viral replication in untreated HIV-1 patients will persistently prevent immunological deterioration and disease progression. Methods: Ongoing multi-centre cohort study in untreated HIV-1 patients with low virus replication. Entry criteria were a persistent viral load (VL) level 600/l to
- Page 1 and 2:
European Journal of Medical Researc
- Page 3 and 4:
Instructions to Authors 1. The Euro
- Page 6 and 7:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 8 and 9:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 10 and 11:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 12 and 13:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 14 and 15:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 16 and 17:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 18 and 19: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 20 and 21: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 22 and 23: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 24 and 25: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 26 and 27: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 28 and 29: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 30 and 31: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 32 and 33: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 34 and 35: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 36 and 37: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 38 and 39: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 40 and 41: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 42 and 43: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 44 and 45: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 46 and 47: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 48 and 49: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 50 and 51: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 52 and 53: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 54 and 55: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 56 and 57: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 58 and 59: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 60 and 61: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 62 and 63: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 64 and 65: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 66 and 67: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 70 and 71: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 72 and 73: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 74 and 75: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 76 and 77: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 78 and 79: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 80 and 81: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 82 and 83: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 84 and 85: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 86 and 87: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 88 and 89: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 90 and 91: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 92 and 93: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 94 and 95: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 96 and 97: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 98 and 99: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 100 and 101: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 102 and 103: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 104 and 105: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 106 and 107: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 108 and 109: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 110 and 111: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 112 and 113: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 114 and 115: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 116 and 117: June 27, 2007 EUROPEAN JOURNAL OF M
- Page 118 and 119:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 120 and 121:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 122 and 123:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 124 and 125:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 126 and 127:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 128 and 129:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 130 and 131:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 132 and 133:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 134 and 135:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 136 and 137:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 138 and 139:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 140 and 141:
June 27, 2007 EUROPEAN JOURNAL OF M
- Page 142 and 143:
June 27, 2007 EUROPEAN JOURNAL OF M